Cite
HARVARD Citation
Di Bacco, A. et al. (2020). C‐MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide‐dexamethasone in myeloma. European journal of haematology. pp. 35-46. [Online].